Restanza's New Hope: Advance Life Sciences To Conduct New Pivotal Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Company sees options in recommendations from FDA advisory committees for community-acquired bacterial pneumonia and for use of animal efficacy rule for biodefense indications.
You may also be interested in...
Forest's Unlikely Co-Sponsor For Ceftaroline Review: FDA Steps In
FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data. Reprinted from The RPM Report, November 2010.
Forest's Unlikely Co-Sponsor For Ceftaroline Review: FDA Steps In
FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data. Reprinted from The RPM Report, November 2010.
Advanced Life Sciences To Pursue New Countermeasure Fund
Restanza developer says it plans to apply for venture funds under new HHS program for small companies developing novel medical countermeasures.